<DOC>
	<DOCNO>NCT00003869</DOCNO>
	<brief_summary>Randomized phase III trial determine effectiveness carboxyamidotriazole treating patient stage III stage IV non-small cell lung cancer . Chemotherapeutic agent modestly effective treatment advance lung cancer , rapid tumor relapse growth even initial response therapy . It yet know whether carboxyamidotriazole effective treatment standard chemotherapy non-small cell lung cancer .</brief_summary>
	<brief_title>Carboxyamidotriazole Treating Patients With Stage III Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether oral administration carboxyaminoimidazole ( CAI ) effective placebo prolong overall survival patient non-small cell lung cancer stage III stage IV non-small cell lung cancer stable tumor regression follow chemotherapy . SECONDARY OBJECTIVES : I . To evaluate safety tolerability oral CAI follow chemotherapy . II . To determine whether CAI prolongs time-to-disease progression relative placebo . III . To evaluate whether substantive effect quality life ( QOL ) detect CAI placebo group use FACT-L UNISCALE . IV . To document response rate CAI patient measurable evaluable disease . TERTIARY OBJECTIVES : I . To evaluate genotype GSH-related locus predictor overall survival . OUTLINE : This randomize , double-blind , multicenter study . Patients stratify accord time first-line therapy ( prior registration v registration ) , disease stage ( IIIA vs IIIB v IV ) , therapy component ( chemotherapy thoracic radiotherapy v chemotherapy ) , ECOG performance status ( 0 vs 1 v 2 ) participate center . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral carboxyamidotriazole daily . ARM II : Patients receive oral placebo daily . Treatment continue absence disease progression unacceptable toxicity . Quality life assess baseline monthly study . Patients follow every 3 month 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboxyamido-triazole</mesh_term>
	<criteria>TRACK I : Histologically cytologically confirm NSCLC stage III IV ; disease must stable respond standard chemotherapy ( without TRT ) minimum 3 maximum 6 month TRACK I : Not require measurable evaluable disease study entry TRACK I : Must one one prior chemotherapy regimen NSCLC ( radiosensitizers allow ) TRACK I : = &lt; 6 week last dose chemotherapy TRT TRACK I : ECOG PS 0 , 1 , 2 TRACK I : ANC &gt; = 1500/mm^3 TRACK I : PLT &gt; = 100,000/mm^3 TRACK I : HgB &gt; = 10.0 g/dL TRACK I : Total bilirubin = &lt; 1.5 x UNL TRACK I : Alkaline phosphatase = &lt; 3 x UNL TRACK I : AST = &lt; 3 x UNL TRACK I : Creatinine = &lt; 1.5 x UNL TRACK I : Expected survival least three month TRACK II AT REGISTRATION : Histologically cytologically confirm NSCLC stage III IV TRACK II AT REGISTRATION : No prior chemotherapy NSCLC TRACK II AT REGISTRATION : Expected survival least six month TRACK II AT REGISTRATION : Willingness provide blood sample TRACK II AT RANDOMIZATION : STAB , PR , CR , REGR follow 36 month chemotherapy without radiation therapy TRACK II AT RANDOMIZATION : Must one one prior chemotherapy regimen NSCLC ( radiosensitizers allow ) TRACK II AT RANDOMIZATION : = &lt; 6 week last dose chemotherapy TRT TRACK II AT RANDOMIZATION : ECOG PS 0 , 1 , 2 TRACK II AT RANDOMIZATION : ANC &gt; = 1500/mm^3 TRACK II AT RANDOMIZATION : PLT &gt; = 100,000/mm^3 TRACK II AT RANDOMIZATION : HgB &gt; = 10.0 g/dL TRACK II AT RANDOMIZATION : Total bilirubin = &lt; 1.5 x UNL TRACK II AT RANDOMIZATION : Alkaline phosphatase = &lt; 3 x UNL TRACK II AT RANDOMIZATION : AST = &lt; 3 x UNL TRACK II AT RANDOMIZATION : Creatinine = &lt; 1.5 x UNL TRACK II AT RANDOMIZATION : Expected survival least three month TRACK I : Pregnant , nursing woman , female sexual partner childbearing potential use adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) study treatment two month discontinue study treatment regimen may harmful develop fetus nursing child TRACK I : Untreated brain metastasis TRACK I : Concomitant participation phase III lung cancer treatment trial TRACK I : Planned concurrent chemotherapy , immunotherapy radiotherapy TRACK II AT RANDOMIZATION : Pregnant , nursing woman , female sexual partner childbearing potential use adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , abstinence , etc . ) study treatment two month discontinue study treatment regimen may harmful develop fetus nursing child TRACK II AT RANDOMIZATION : Untreated brain metastasis TRACK II AT RANDOMIZATION : Planned concurrent chemotherapy , immunotherapy , radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>